492 related articles for article (PubMed ID: 32306207)
1. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.
Singh RR; O'Reilly EM
Drugs; 2020 May; 80(7):647-669. PubMed ID: 32306207
[TBL] [Abstract][Full Text] [Related]
2. Targeting DNA damage repair pathways in pancreas cancer.
Crowley F; Park W; O'Reilly EM
Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapeutic options for pancreatic ductal adenocarcinoma.
Sardar M; Recio-Boiles A; Mody K; Karime C; Chandana SR; Mahadevan D; Starr J; Jones J; Borad M; Babiker H
Expert Opin Pharmacother; 2022 Dec; 23(18):2079-2089. PubMed ID: 36394449
[TBL] [Abstract][Full Text] [Related]
4. Treatment landscape of metastatic pancreatic cancer.
De Dosso S; Siebenhüner AR; Winder T; Meisel A; Fritsch R; Astaras C; Szturz P; Borner M
Cancer Treat Rev; 2021 May; 96():102180. PubMed ID: 33812339
[TBL] [Abstract][Full Text] [Related]
5. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions.
Giordano G; Pancione M; Olivieri N; Parcesepe P; Velocci M; Di Raimo T; Coppola L; Toffoli G; D'Andrea MR
World J Gastroenterol; 2017 Aug; 23(32):5875-5886. PubMed ID: 28932079
[TBL] [Abstract][Full Text] [Related]
6. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Ellenrieder V; König A; Seufferlein T
Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
[TBL] [Abstract][Full Text] [Related]
7. Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
Rémond MS; Pellat A; Brezault C; Dhooge M; Coriat R
ESMO Open; 2022 Dec; 7(6):100638. PubMed ID: 36399952
[TBL] [Abstract][Full Text] [Related]
8. Pancreas cancer: Therapeutic trials in metastatic disease.
Smithy JW; O'Reilly EM
J Surg Oncol; 2021 May; 123(6):1475-1488. PubMed ID: 33831245
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges.
Diab M; Azmi A; Mohammad R; Philip PA
Expert Opin Pharmacother; 2019 Apr; 20(5):535-546. PubMed ID: 30592647
[TBL] [Abstract][Full Text] [Related]
10. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer.
Nevala-Plagemann C; Hidalgo M; Garrido-Laguna I
Nat Rev Clin Oncol; 2020 Feb; 17(2):108-123. PubMed ID: 31705130
[TBL] [Abstract][Full Text] [Related]
11. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
[TBL] [Abstract][Full Text] [Related]
12. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D
BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394
[TBL] [Abstract][Full Text] [Related]
13. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.
Singh RR; Goldberg J; Varghese AM; Yu KH; Park W; O'Reilly EM
Cancer Treat Rev; 2019 May; 75():27-38. PubMed ID: 30927677
[TBL] [Abstract][Full Text] [Related]
14. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
15. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
16. Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives.
Lellouche L; Palmieri LJ; Dermine S; Brezault C; Chaussade S; Coriat R
Ther Adv Med Oncol; 2021; 13():17588359211018539. PubMed ID: 34285720
[TBL] [Abstract][Full Text] [Related]
17. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
Front Immunol; 2018; 9():1878. PubMed ID: 30158932
[TBL] [Abstract][Full Text] [Related]
19. Metastatic pancreatic cancer: Is there a light at the end of the tunnel?
Vaccaro V; Sperduti I; Vari S; Bria E; Melisi D; Garufi C; Nuzzo C; Scarpa A; Tortora G; Cognetti F; Reni M; Milella M
World J Gastroenterol; 2015 Apr; 21(16):4788-801. PubMed ID: 25944992
[TBL] [Abstract][Full Text] [Related]
20. Next-generation therapies for pancreatic cancer.
Buckley CW; O'Reilly EM
Expert Rev Gastroenterol Hepatol; 2024; 18(1-3):55-72. PubMed ID: 38415709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
